NIH statement on editing human embryo DNA |
The recent reiteration by the Director of
the NIH, Dr. Francis Collins, that the long held legal position of the US
Federal Government is to not fund destructive embryo research,
brings the US debate on germ line editing front & center in practical
terms.
"Use" of human embryos, for their own
benefit, is written into the established Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 Recital(42) on the legal protection of biotechnological
inventions in European states et al and is a foundational document addressing
this area. The interpretation of this document has led to the European Patent
Office guidelines and appeal rulings.
However, apart
from the embryo "use" issue, the Directive (Chapter 6.2.b)
specifically states that "processes for modifying the germ line genetic
identity of human beings" are prohibited from Patentability.
Also, the "Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine Oviedo,4.IV.1997" states "An intervention seeking to modify the
human genome may only be undertaken for preventive, diagnostic or therapeutic
purposes and only if its aim is not to introduce any modification in the genome
of any descendants." This forms part of the overall European Convention on Human Rights, in
all its parts "The Convention."
So in Europe
the issue of Human Rights & Innovation Patentability are determined by
guideline standards applied mainly throughout the membership via The
Convention & the BioTech Directive, while Individual National Laws are
deferred to, fundamentally by design, in determining the applicable
interpretations & standards governing the specific ethical/moral &
"ordre public" of that society in biomedical research.
In the US, it's also the actual "use" of embryos for research, including the derivation itself of ESCs, that is the Federal funding restriction. This is a result of, exclusively at the time of drafting, the destructive method employed to derive hESC lines. In addition research funding into destructive embryo studies in areas such as nuclear transfer & genetic modifications of the germ line were also restricted, as a result. The reiteration of this established position recently by the NIH reminds all of the reality of the current funding law governing destructive practices on "human embryos."
In the US, it's also the actual "use" of embryos for research, including the derivation itself of ESCs, that is the Federal funding restriction. This is a result of, exclusively at the time of drafting, the destructive method employed to derive hESC lines. In addition research funding into destructive embryo studies in areas such as nuclear transfer & genetic modifications of the germ line were also restricted, as a result. The reiteration of this established position recently by the NIH reminds all of the reality of the current funding law governing destructive practices on "human embryos."
However, historically
there has been somewhat of a mixed approach in practice applied to federally
funded embryonic research in the US. The NIH has authorized funding for decades
using donated IVF supernumerary embryonic stem cell lines for research. On the
one hand the law states that no funding is allowed that destroys embryos (e.g.
blastocyst ICM extraction of stem cells, or in this most recent case genetic
editing on embryos that would result in their destruction). However, on the
other hand, this law doesn't apply when work is done on Federal registry
approved embryonic stem cell lines (see NIH guidelines). This
reality is a middle way compromise to support the nascent field of advanced
research into developmental biology and has resulted in significant progress in
the understanding and therapeutic potential of pluripotent cell technologies.
Of note, more
recent non-destructive methods, nor research using non-viable embryos, have yet to be written in. For example, non-embryo-destructive sourced Blastomere ESCs,
nor non-viable SCNT-ESCs or Parthenogenetics-hpESCs, are notably excluded from federal
support. So the actual working model isn't that current nor flexible to the
evolving technology, which is reason to review the legislature as a result of
the sector’s broadening scope.
The use of
natural eggs in SCNT-ESCs/hpESCs was perhaps the concern and avowed aspect of
these methods to the Federal Government - but has there been a recent review on
this position given IVF has become a standard option in fertility treatment?
Also the sector is moving fast and emerging reprogramming techniques look to
create synthetic eggs, what then? Is this not a reasonable question to be
asking now, given the discussion?
This line can and may very well be taken further with
technology to create synthetic sperm. Will the combination of synthetic eggs
and sperm be the next ethical issue? I believe there needs to be a concerted
effort to get ahead of the science & write updated Laws that apply new
guidelines with scientifically prudent standards, while remaining open and
flexible to potential benefit & future possibilities.
Further, the European Court of Justice has ruled recently that non-viability is a determining
characteristic of the definition of a "human embryo," therefore
non-viable zygotes & arrested/mutated pre-embryos that cannot develop do
not fall within the restrictions of the Biotechnology Directive, as they have
been ruled not to be considered by definition an "human embryo."
However controversial this position may seem to some it is an accurate reflection
and interpretation of the foundational biotechnology law in Europe, while
deferring to national member states the issue of ethical/moral &
"ordre public."
Fundamentally the underlying principles of the
protection of life in the Chapter 1 Article 2 of The Convention doesn't state explicitly that germ line cells, nor for that matter an embryo or
fetus, are to be given specific reserved consideration. This has been tested at
the European Court of Human Rights.
Should national laws allow in-vitro research on embryos The Convention states in Chapter 5 Article 18 that they should "ensure adequate protection of
the embryo" and that "the creation of human embryos for research
purposes is prohibited." This is the general positioning at the European
Human Rights level, as a result of the union of culturally diverse member
states. As previously indicated, individual countries apply local Laws to their societal ethical positions, which they all do in regard to embryos/ESCs, genetics,
IVF & fetal development, considering The Convention. Generally the
principle of human rights & dignity extends to all human beings and for
that the definition of a "human being" is central to The Convention's
interpretation. The UN's Universal Declaration of Human Rights is similarly worded and looks to respect individual
human rights, while leaving the question of developing life to individual
societies.
With regard to cloning there was a specific Protocol added to The Convention in
1998, and enacted by other governing bodies internationally, as a result of the
discussions surrounding animal cloning at the time. Specifically, The
Convention states that "any intervention seeking to create a human being
genetically identical to another human being, whether living or dead, is
prohibited."
The objections
to assisted reproduction by the Vatican or Christian Right may very well be subjectively valid, from their reasoned perspective, but that view, however
correct or positioned to be morally sound, doesn't acknowledge nor properly
address the very real practical issues inherent in today's advanced fertility,
cell & genetic sciences. Many of the issues previously debated are being
clinically applied with results. New ethical challenges and redefinitions are
required by all as the science evolves, with appropriate regulatory &
societal frameworks adapted, as necessary.
The fact that new technological advancements are being
designed to address medical needs of those that suffer from, or may fall victim
to, potentially treatable biological conditions warrants considered thought as
to how best to unify behind the effort to achieve a host of goals in the
process. Through public education and the application of successful next
generation technology the substance and impact science can have on solving the
very issues that divides opinion is possible.
The ethics of today will give way to the ethics of
tomorrow, and so on - it's nature's way. Man plays his part in this cycle and
uses what is available with intellect and inventiveness. Change is a process of
adjustment and one could say that is the will of nature's law. The only
unnatural aspect would be if man himself becomes defined as synthetic, which
is, from this writer's perspective not the goal.
Germ line editing in clinical practice is indeed
unnecessary at present until proven otherwise. However, basic research using
gene editing technology of germ line cells is necessary, based on clearly
defined updated ethical frameworks - with governmental support, if possible. The recent ISSCR Connect discussion on the issue was well presented and reasoned. More open dialogue
is required and opinion sought from all stakeholders. There are too many
questions yet unanswered to not search for the clues by all means so one day we
may apply that knowledge to human frailty & suffering in developing or
developed humans. That goal would be best served by furthering basic research
efforts using genetics back to our original cells. iPS technology wouldn't have
been invented had it not been for human embryonic research, which wouldn't have
been possible without animal cloning studies…. the shoulders' metaphor applies.
From my perspective if gene editing research using germ line cells and pre-embryos is to be limited entirely to private companies then that would curtail potential scientific progress in research using non-viable donations or technology methods which cannot develop into a human by design.
From my perspective if gene editing research using germ line cells and pre-embryos is to be limited entirely to private companies then that would curtail potential scientific progress in research using non-viable donations or technology methods which cannot develop into a human by design.
Congress has
the opportunity to get ahead of these issues and address squarely this area of leading biotechnology innovation in new legislation. This was shown to be
important during the protracted court case against the Federal Govt.’s funding
of scientific research using approved hESC lines. The high court ruled in favor of the Govt. but there was considerable
discussion in legal circles of the need to update the law. The underlying legal
basis being the Dickey Wicker amendment, which was written in 1995, and is considered by many to
be too ambiguous and not a suitable
legislative document for the sector moving forward. The need for a
comprehensive bill is generally acknowledged. The use of Federal funds in
developmental biology research should allow for opportunities to explore all non-destructive
areas of the science to advance medical knowledge so that it does not impede
the progress of scientific discovery for the benefit of all. Patients'
interests must be considered paramount and consensus sought on majority based
positioning. Public education can be an effective tool in defining such
efforts.
For example, currently there is an area of ambiguity
with the written NIH hESC text on embryo donations, as a cell can be harvested
from a pre-embryo and used for that embryo's own benefit, if not for all.
Ethical considerations are required to be taken into
account, but not at the expense of an agreed roadmap to progress. If after
broad inclusive deliberations legislative regulations & sector guidelines
are updated, then that achieves the goal. However, I would add a caveat, it’s
important to include into any new laws the non-viable/non-destructive aspects
succinctly, as well as a considered inclusion of a benefit review for technologies
applied to viable potential human embryos in-vitro & in-vivo.
However, "use" of embryos isn't the full picture. There remain issues of scope with respect to reprogramming technology, assisted reproduction techniques et al which should be clearly stated as part of new regulations & guidelines in the area.
However, "use" of embryos isn't the full picture. There remain issues of scope with respect to reprogramming technology, assisted reproduction techniques et al which should be clearly stated as part of new regulations & guidelines in the area.
Clarification is needed as to the somatic
reprogramming limits that are acceptable and where there should be restrictions,
if any, applied. Synthetic forms of human germ line cells and the creation of
pure or part-synthetic embryos for cellular harvest cannot be overlooked and
needs similarly considered language. Issues such as same sex couples wishing to
use technology to assist having "natural" babies using reprogrammed
cells back to the germline, artificial wombs and attempts at eugenics et al
should be broadly covered in the legislative language.
If there were clear legislature on the issues, after
dialogue with all stakeholders, this would assist in eliminating the negative
spin on today's advancing scientific discoveries that looks squarely to cure
disease. Science would benefit from that clarity. The future possibilities
would remain, however, guidelines would be established.
Consider if you
will that if the science advances and we are able to achieve that long string
of .999s on safety, what will be the benefit/risk scenario if implementation
occurs some time in the future? Such science can be debated at that point and
submitted for consideration, as long as there's a benefit window.
Generally in the future there may be a manner in which
genetic technology proves its human potential for the application of germ line
intervention. Leaving that door closed while holding a preexisting key isn't
such an unethical position IMO - flexibility in today's fast paced scientific
world is important.
The challenge in establishing regulations in this area
will not be easy, but it isn't insurmountable. A flexible legal &
regulatory basis for steps forward in the research is what is required IMO.
Checkpoints along the way so that the whole map is not null if one road is
opened up upon the presentation of correct documentation. A straightforward
mechanism should be agreed for the review process that encompasses the
appropriate nominated bodies. Congressional oversight may be appropriate but
the nature of such a flexible system would be best served to have it's own
adaptation authority once the law is written.
I have stated previously that the reduction in IVF
supernumerary embryo creation should be a stated goal with new specific
governance stipulations & authority guidelines over the fertility sector.
This I believe is central to a consensus building working
model.
The point is we as a society cannot any longer avoid
the reality of the present and promise of the future by applying yesterday's
fixed reasoning to bear. Without informed, concise & regularly updated
language of the day the necessary support and freedom to research innovative
solutions to pressing medical and biological issues will be unnecessarily
limited.
Today the US is the leader in ethical biomedical
technology but without Bold Action, Decisive New Legislature and Increased
Government Support, across the board, the promise of tomorrow's technology with
not meet the expectations of the people nor address the full potential for
American solutions for the Common Good.
Cheers
References:
- Statement on NIH funding of research using gene-editing technologies in human embryos
- National Institutes of Health Guidelines on Human Stem Cell Research
- European Convention on Human Rights ("The Convention")
- Prohibition of Cloning Human Being
- Convention on HumanRights and Biomedicine, Oviedo, 4.IV.1997
- Dir 98/44/EC European Parliament/Council '98: Legal Protection Biotech Inventions
- European Court of Justice ruling on Parthenotes as not "human embryos"
- Council of Europe -Steering Committee on Bioethics: In Vitro Embryo Protection
- United Nations: The Universal Declaration of Human Rights
- European Court of Human Rights
- Dickey Wicker Amendment
- US Supreme Court ensures continued US funding of human embryonic-stem-cell research
- Genetic Modifications in Humans:The Scientific Methods, Medical Applications and Ethical Implications (ISSCR Connect Video On Demand: Dr. George Daley & Prof. Timothy Caulfield)
- European regulatory map on ES research via Eurostemcell.org